Century Therapeutics, Inc. (IPSC) Income Statement
IPSC 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIPSC revenue and net income
Where IPSC's revenue goes
2025Each bar shows an amount and its share of revenue. IPSC kept −8.8% of revenue as net income.
IPSC profit margins
IPSC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1,556.8% | +175.9% | — | — |
| Gross profit | +1,357.9% | +164.4% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IPSC quarterly EPS vs estimates
Century Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.12).
IPSC income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | $1.1M | $0 | $0 | $470.3M | $950.8M |
| Cost of revenue | $13.1M | $13.3M | $13.0M | $10.1M | $4.6M | $1.8M | $249,000 | $467.8M | $888.8M |
| Gross profit | $96.1M | $6.6M | $2.2M | $5.2M | −$4.6M | −$1.8M | −$249,000 | $2.5M | $62.0M |
| Research & development | $95.7M | $107.2M | $92.7M | $97.2M | $75.6M | $39.7M | $14.3M | $9.1M | $11.4M |
| Sales, general & admin | $24.0M | $33.2M | $47.8M | $31.9M | $19.2M | $9.5M | $5.8M | $81.4M | $108.8M |
| Total operating expenses | $111.1M | $144.7M | $148.8M | $139.0M | $90.3M | $47.4M | $19.8M | — | — |
| Operating income | −$15.0M | −$138.1M | −$146.5M | −$133.8M | −$94.9M | −$49.2M | −$20.0M | — | — |
| Interest income | $7.3M | $13.0M | $12.7M | $4.4M | — | — | — | — | — |
| Interest expense | — | $0 | $540,000 | $1.1M | $1.3M | $381,000 | $0 | $0 | $0 |
| Income before taxes | −$9.6M | −$124.8M | −$134.8M | −$130.8M | −$95.8M | −$53.6M | −$244.8M | — | — |
| Income taxes | −$68,000 | $1.8M | $1.9M | $91,000 | $43,000 | $1.1M | $1.2M | — | — |
| Net income | −$9.6M | −$126.6M | −$136.7M | −$130.9M | −$95.8M | −$53.6M | −$244.8M | — | — |
| EBITDA | $3.5M | −$111.5M | −$121.2M | −$121.2M | −$90.8M | −$51.8M | −$244.5M | — | — |
| EPS (diluted) | −$0.06 | −$1.63 | −$2.22 | −$3.82 | −$5.04 | −$0.95 | −$0.51 | — | — |
| Gross margin | 88.0% | 100.0% | 100.0% | 100.0% | −433.1% | — | — | 0.5% | 6.5% |
| Operating margin | −13.8% | −2,096.5% | −6,556.9% | −2,574.2% | −8,968.1% | — | — | — | — |
| Net margin | −8.8% | −1,920.9% | −6,115.1% | −2,518.4% | −9,057.1% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $109.2M | $4.2M | $791,000 | $771,000 | $855,000 | $268,000 | $148,000 |
| Cost of revenue | — | $3.0M | $3.5M | $22.5M | $26.9M | $0 | $3.3M | $3.3M | $3.5M | $3.2M | $22.3M | $22.8M |
| Gross profit | — | −$3.0M | −$3.5M | −$22.5M | −$26.9M | $109.2M | $4.2M | $791,000 | $771,000 | $855,000 | −$22.0M | −$22.6M |
| Research & development | $19.6M | $14.1M | $19.7M | $22.5M | $26.9M | $26.6M | $29.4M | $27.2M | $27.2M | $23.4M | $23.3M | $26.8M |
| Sales, general & admin | $5.8M | $6.6M | $956,000 | $6.8M | $7.8M | $8.4M | $8.5M | $8.4M | $8.3M | $8.7M | $8.6M | $9.0M |
| Total operating expenses | $36.5M | $22.5M | $20.7M | $13.6M | $7.8M | $35.0M | $41.5M | $35.6M | $35.5M | $32.2M | $21.7M | $13.0M |
| Operating income | −$36.5M | −$25.5M | −$20.7M | −$36.1M | −$34.7M | $74.2M | −$37.3M | −$34.8M | −$34.8M | −$31.3M | −$43.8M | −$35.6M |
| Interest income | $2.0M | $2.0M | $1.3M | $1.6M | $2.0M | $2.4M | $2.9M | $3.3M | $3.6M | $3.2M | $3.5M | $3.5M |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $1.1M | $0 |
| Income before taxes | −$34.5M | −$21.6M | −$19.2M | −$34.4M | −$32.5M | $76.6M | −$34.3M | −$31.2M | −$31.2M | −$28.1M | −$40.3M | −$32.1M |
| Income taxes | — | — | −$68,000 | — | — | — | $1.8M | −$8,000 | $22,000 | $1,000 | −$869,000 | $592,000 |
| Net income | −$34.5M | −$21.6M | −$19.2M | −$34.4M | −$32.5M | $76.6M | −$36.1M | −$31.2M | −$31.2M | −$28.1M | −$39.4M | −$32.7M |
| EBITDA | −$31.9M | −$18.6M | −$15.7M | −$26.2M | −$29.3M | $79.8M | −$31.0M | −$27.9M | −$27.7M | −$24.8M | −$27.1M | −$28.3M |
| EPS (diluted) | −$0.17 | −$0.11 | −$0.25 | −$0.32 | −$0.38 | $0.89 | −$0.43 | −$0.37 | −$0.38 | −$0.45 | −$0.65 | −$0.55 |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −8,219.4% | −15,297.3% |
| Operating margin | — | — | — | — | — | 67.9% | −893.5% | −4,398.1% | −4,507.8% | −3,661.9% | −16,329.1% | −24,071.6% |
| Net margin | — | — | — | — | — | 70.1% | −864.4% | −3,947.7% | −4,047.6% | −3,282.1% | −14,700.7% | −22,108.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IPSC's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IPSC financial results
In fiscal year 2025 (ended December 31, 2025), Century Therapeutics reported revenue of $109.2 million, up 1,556.8% from the year before. It had a net loss of $9.6 million, a net profit margin of −8.8%. Diluted earnings per share came to −$0.06.
See the IPSC stock overview for the latest quote and news, or the IPSC chart for price history and technical indicators.
IPSC income statement FAQ
What is Century Therapeutics's annual revenue?
Century Therapeutics reported total revenue of $109.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 1,556.8% from $6.6 million the previous year.
Is Century Therapeutics profitable?
No. Century Therapeutics reported a net loss of $9.6 million in fiscal 2025, a net profit margin of −8.8%; its operating margin was −13.8%.
What is Century Therapeutics's gross margin?
Century Therapeutics's gross margin was 88.0% in fiscal 2025: for every $100 of revenue, Century Therapeutics kept $88 after the direct cost of its products and services.
How much does Century Therapeutics spend on research and development?
Century Therapeutics spent $95.7 million on research and development in fiscal 2025, 87.6% of revenue.
What are Century Therapeutics's earnings per share?
Century Therapeutics earned $-0.06 per diluted share in fiscal 2025, compared with $-1.63 a year earlier.
When will Century Therapeutics report its next earnings?
Century Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Century Therapeutics's fiscal year end?
Century Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.